Securities code: 002275 securities abbreviation: Guilin Sanjin Pharmaceutical Co.Ltd(002275) Announcement No.: 2022-005
Guilin Sanjin Pharmaceutical Co.Ltd(002275) 2021 annual performance express
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special tips:
The financial data of 2021 contained in this announcement is only preliminary accounting data, which has been audited by the company’s internal audit department and has not been audited by an accounting firm. It may be different from the final data disclosed in the 2021 annual report. Investors are reminded to pay attention to investment risks. 1、 Main financial data and indicators in 2021
Unit: Yuan
Increase / decrease range of the project in the same period of last year in the reporting period (%)
Total operating income 1767363870.33 1566484673.44 12.82%
Operating profit 445203274.96 354738785.77 25.50%
Total profit 445120335.64 344165074.30 29.33%
Net profit attributable to shareholders of listed company 348257872.01 277020898.87 25.72%
Net profit attributable to shareholders of the company in the city of 293135274.66 252240992.83 16.21% after deducting non recurring profits and losses
Basic earnings per share (yuan) 0.61 0.48 27.08%
Weighted average return on net assets 12.16%, 9.63%, 2.53%
Increase / decrease range at the end of the reporting period (%)
Total assets 4114113124.04 3882273181.59 5.97%
Ownership rights attributable to shareholders of listed companies 2844407991.65 2959001855.77 – 3.87% profit
Share capital 59020000.00 59020000.00 0.00%
Net capital per share attributable to shareholders of listed companies 4.94 5.14 – 3.89% (yuan)
Note: the above basic earnings per share (yuan), weighted average return on net assets and net assets per share attributable to shareholders of the listed company (yuan) are calculated according to the total share capital after deducting the number of repurchased shares.
2、 Description of operating performance and financial status
During the reporting period, the company achieved an operating revenue of 1767363900 yuan, an increase of 12.82% over the same period of last year; The total profit was 44.51203 million yuan, an increase of 29.33% over the same period of last year; The net profit attributable to the shareholders of the listed company was 348.2579 million yuan, an increase of 25.72% over the same period last year. The company’s operating indicators increased significantly, mainly due to the severe market environment during the reporting period. The company actively responded to the impact of the epidemic, strengthened promotion and sales, and effectively controlled costs. At the same time, the government also gave strong support to the enterprise. In 2021, the company received more government subsidies, and confirmed other income of RMB 64.0133 million, an increase of 155.38% over the previous period.
3、 Description of the difference from the previous performance forecast
Before the disclosure of this performance express, the company has not made any expected disclosure on the performance of 2021.
4、 Documents for future reference
1. Comparative balance sheet and income statement signed and sealed by the current legal representative of the company, the person in charge of accounting and the person in charge of accounting organization (Accounting Supervisor);
2. The internal audit report signed by the head of the internal audit department.
It is hereby announced.
Guilin Sanjin Pharmaceutical Co.Ltd(002275)
Board of directors
February 25, 2022
